Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.55 |
| ▸ | CA1 | P00915 | 12/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | CA5A | P35218 | 3/20 | 0.41 |
| ▸ | CA6 | P23280 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139590 | 0.80 | HPGD (0.51) | CA2CA1LMNACA9CA5A | |
| SCHEMBL138368 | 0.78 | LMNA (0.68) | CA2CA1LMNA | |
| SCHEMBL140457 | 0.77 | PTGS1 (0.50) | CA2LMNA | |
| SCHEMBL140452 | 0.77 | MEN1 (0.55) | CA2LMNA | |
| SCHEMBL138377 | 0.77 | NPSR1 (0.46) | CA2LMNA | |
| SCHEMBL20906520 | 0.74 | CA2 (0.64) | CA2CA1LMNACA9CA12 | |
| SCHEMBL29704099 | 0.74 | CA2 (0.46) | CA2CA1PTGES2CA9CA5A | |
| SCHEMBL3363314 | 0.74 | CA2 (0.49) | CA2CA1PTGES2CA9CA5A | |
| SCHEMBL3528916 | 0.74 | CA2 (0.46) | CA2CA1PTGES2CA9CA5A | |
| SCHEMBL138372 | 0.73 | KDM4E (0.61) | CA2CA1LMNACA9CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307454-A1 | Sulfonamide Compound | KALLYOPE, INC. | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307454-A1 | Sulfonamide Compound | TRPM8, TRPM5, TRPM7 | CA2 114/4885CA1 655/4885PTGES2 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.